Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic
Open Access
- 5 October 2023
- journal article
- research article
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 16 (12) , 1942-1946
Abstract
No abstract availableKeywords
Funding Information
- National Cheng Kung University Hospital
This publication has 13 references indexed in Scilit:
- Antiviral Drug Discovery for the Treatment of COVID-19 InfectionsViruses, 2022
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19New England Journal of Medicine, 2022
- Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal modelsReproductive Toxicology, 2022
- Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boostEmerging Microbes & Infections, 2022
- Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variantsScience, 2021
- Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escapeNature Reviews Immunology, 2021
- Major Update: Remdesivir for Adults With COVID-19Annals of Internal Medicine, 2021
- Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19)Obstetrics & Gynecology, 2021
- Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019Clinical Infectious Diseases, 2020
- Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysisBMJ, 2020